Display options
Cite
Ruddy KJ, Schaid DJ, Batzler A, et al. Antimullerian Hormone as a Serum Biomarker for Risk of Chemotherapy-Induced Amenorrhea. J Natl Cancer Inst. 2021;113(8):1105-1108doi: 10.1093/jnci/djaa160.
Ruddy, K. J., Schaid, D. J., Batzler, A., Cecchini, R. S., Partridge, A. H., Norman, A., Fehrenbacher, L., Stewart, E. A., Trabuco, E., Ginsburg, E., Couch, F. J., Fasching, P. A., Vachon, C., & Ganz, P. A. (2021). Antimullerian Hormone as a Serum Biomarker for Risk of Chemotherapy-Induced Amenorrhea. Journal of the National Cancer Institute, 113(8), 1105-1108. https://doi.org/10.1093/jnci/djaa160
Ruddy, Kathryn J, et al. "Antimullerian Hormone as a Serum Biomarker for Risk of Chemotherapy-Induced Amenorrhea." Journal of the National Cancer Institute vol. 113,8 (2021): 1105-1108. doi: https://doi.org/10.1093/jnci/djaa160
Ruddy KJ, Schaid DJ, Batzler A, Cecchini RS, Partridge AH, Norman A, Fehrenbacher L, Stewart EA, Trabuco E, Ginsburg E, Couch FJ, Fasching PA, Vachon C, Ganz PA. Antimullerian Hormone as a Serum Biomarker for Risk of Chemotherapy-Induced Amenorrhea. J Natl Cancer Inst. 2021 Aug 02;113(8):1105-1108. doi: 10.1093/jnci/djaa160. PMID: 33159444; PMCID: PMC8328977.
Copy Download .nbib Format: NLM
Share it on

J Natl Cancer Inst. 2021 Aug 02;113(8):1105-1108. doi: 10.1093/jnci/djaa160.

Antimullerian Hormone as a Serum Biomarker for Risk of Chemotherapy-Induced Amenorrhea.

Journal of the National Cancer Institute

Kathryn J Ruddy, Daniel J Schaid, Anthony Batzler, Reena S Cecchini, Ann H Partridge, Aaron Norman, Louis Fehrenbacher, Elizabeth A Stewart, Emanuel Trabuco, Elizabeth Ginsburg, Fergus J Couch, Peter A Fasching, Celine Vachon, Patricia A Ganz

Affiliations

  1. Department of Oncology, Mayo Clinic, Rochester, MN, USA.
  2. Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
  3. Department of Biostatistics, University of Pittsburgh, Pittsburgh, PA, USA and NRG Oncology, Pittsburgh, PA, USA.
  4. Division of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  5. Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
  6. Kaiser Permanente Oncology Clinical Trials, Vallejo, CA, USA.
  7. Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN, USA.
  8. Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Boston, MA, USA.
  9. Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
  10. Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-European Metropolitan Region of Nuremberg, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
  11. Jonsson Comprehensive Cancer Center at UCLA, NRG Oncology, Los Angeles, CA, USA.

PMID: 33159444 PMCID: PMC8328977 DOI: 10.1093/jnci/djaa160

Abstract

Antimullerian hormone (AMH) is a promising biomarker for ovarian reserve. In this study, we assessed AMH before and 1 year after initiation of adjuvant chemotherapy on National Surgical Adjuvant Breast and Bowel Project (NSABP)/NRG Oncology B-47 in female participants aged 42 years and younger (median age = 39 years). At baseline, median AMH was 1.2 ng/mL; 13 (4.7%) values were less than 0.1 ng/mL (the threshold for detectable levels, in the perimenopause and menopause range), and 57 values (20.6%) were less than 0.5 ng/mL. At 1 year, 215 (77.6%) were less than 0.1 ng/mL, and 264 (95.3%) were less than 0.5 ng/mL. Postchemotherapy menses were reported by 46.2% of participants. Multivariable logistic regression found that the odds of having postchemotherapy menses increased with younger age, higher body mass index, and higher prechemotherapy AMH, but not by trastuzumab administration or by the choice of chemotherapy (doxorubicin-cyclophosphamide followed by paclitaxel vs docetaxel-cyclophosphamide). We conclude that higher prechemotherapy AMH predicts a lower risk of chemotherapy-induced amenorrhea and that AMH 1 year after chemotherapy initiation is not informative in this setting because it is likely to be very low.

© The Author(s) 2020. Published by Oxford University Press. All rights reserved. For permissions, please email: [email protected].

References

  1. Breast Cancer Res Treat. 2019 Feb;173(3):619-628 - PubMed
  2. Reprod Biomed Online. 2019 Oct;39(4):712-720 - PubMed
  3. Breast Cancer. 2017 Sep;24(5):714-719 - PubMed
  4. Biochem Med (Zagreb). 2011;21(3):219-30 - PubMed
  5. Breast Cancer Res Treat. 2009 Jan;113(2):315-20 - PubMed
  6. Eur J Cancer. 2013 Nov;49(16):3404-11 - PubMed
  7. J Clin Oncol. 2011 Mar 20;29(9):1110-6 - PubMed
  8. Clin Biochem. 2015 Apr;48(6):453-5 - PubMed
  9. Clin Breast Cancer. 2019 Feb;19(1):e74-e84 - PubMed
  10. Cancer Invest. 2008 Apr-May;26(3):286-95 - PubMed
  11. Cancer. 2014 Dec 1;120(23):3691-8 - PubMed
  12. Chin J Cancer Res. 2018 Aug;30(4):468-476 - PubMed
  13. J Clin Oncol. 2020 Feb 10;38(5):444-453 - PubMed
  14. Cancer. 2010 Feb 15;116(4):791-8 - PubMed
  15. Acta Oncol. 2016 Jun;55(6):664-70 - PubMed
  16. J Breast Cancer. 2019 Nov 13;22(4):624-634 - PubMed
  17. Breast Cancer Res Treat. 2014 Apr;144(3):591-7 - PubMed
  18. Fertil Steril. 2012 Jan;97(1):154-9 - PubMed

Publication Types

Grant support